Advancements in the Medical Treatments of Stuttering

Gerald Macguire, MD, Shahriar SheikhBahaei, Ph.D.

Saturday 1:15PM - 2:15PM EDT

Much has been learned in recent months about the unique brain differences we, who stutter, possess. Currently, two pharmacologic agents are in government regu- lated trials with the goals of being the first approved, evidenced-based treatments for stuttering–ecopipam and gemlapodect. As such research and pharmacologic treatments emerge, the stuttering community will likely face less stigma and great- er acceptance as the greater community will gain knowledge of our condition. In addition, those who stutter will be afforded greater access to healthcare as has been seen with other brain conditions such as depression, social anxiety, ADHD and OCD, which co-exist highly in our population.

---

What to expect

At the conclusion of the session, the participants shall be able to:

1. Cite the latest understandings in the brain differences in those who stutter.
2. Review the data and mechanisms of the respective investigational agents in stuttering—ecopipam and gemlapodect.
3. Summarize how the latest research understandings of stuttering will decrease stigma and increase acceptance of stuttering

---

About the presenter